Pharming Group N.V. today announces that its Vice-Chair, Juergen Ernst, has, for personal reasons, decided to retire from the Board of Supervisory Directors (BOSD), effective immediately. Ms. Debora Jorn, a member of the BOSD, will succeed Juergen as Vice-Chair.

Pharming Group N.V. announces it has committed to building a new facility to expand the Company’s downstream processing capacity for its lead product, RUCONEST® (recombinant C1 esterase inhibitor (rhC1INH)).

Pharming Group N.V. announces the appointment of Jeroen Wakkerman as Chief Financial Officer (CFO), with effect from 16 November 2020.

Pharming Group N.V. announces it will hold an Extraordinary General Meeting (EGM) of Shareholders on Friday 11 December 2020 at 14:00 CET.

Pharming Group N.V. presents its (unaudited) financial report for the nine months and third quarter ended 30 September 2020.

Pharming Group N.V. today announces that the European Commission has granted orphan drug designation for leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS), based on a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicine Agency (EMA).

On the 29th of October at 19:00 Pharming’s CEO, Sijmen de Vries will discuss the recently published Q3 2020 financial results, provide a business update and insight into market developments. Submit your questions in advance to investor@pharming.com

Pharming Group N.V. today announces the publication of data in the peer-reviewed journal, Frontiers in Immunology, from a compassionate use program of five patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalized with related severe pneumonia that were treated with RUCONEST® (recombinant human C1 inhibitor, conestat alfa) at the University Hospital Basel, Switzerland.

Pharming Group N.V. announces that the first patient has been enrolled in a randomized, controlled, investigator-initiated clinical trial in up to 150 patients for the treatment with RUCONEST® (recombinant human C1 inhibitor) of patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalized with related severe pneumonia at the University Hospital Basel in Basel, Switzerland.

Pharming Group N.V. presents its (unaudited) financial report for the six months ended 30 June 2020.